Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933865 | 0.90 | PTGDR2 (0.58) | PTGDR2RAB9ATSPOKDM4EALDH1A1 | |
| SCHEMBL935176 | 0.89 | PTGDR2 (0.61) | PTGDR2BCHEACHE | |
| SCHEMBL934574 | 0.87 | PTGDR2 (0.46) | PTGDR2 | |
| SCHEMBL934229 | 0.87 | PTGDR2 (0.61) | PTGDR2MCHR1RAB9APTGESTSPO | |
| SCHEMBL934148 | 0.86 | PTGDR2 (0.54) | PTGDR2RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL934199 | 0.85 | PTGDR2 (0.56) | PTGDR2RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL935192 | 0.84 | PTGDR2 (0.57) | PTGDR2TSPONPC1 | |
| SCHEMBL933849 | 0.84 | PTGDR2 (0.43) | PTGDR2RAB9AALDH1A1HPGDCHRM2 | |
| SCHEMBL934534 | 0.83 | PTGDR2 (0.52) | PTGDR2RAB9APTGESALDH1A1NPC1 | |
| SCHEMBL934502 | 0.81 | PTGDR2 (0.59) | PTGDR2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | PTGDR2 548/4885MCHR1 3242/4885RAB9A 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.